Stem Cell Therapy Shows Safety, Possible Efficacy in Early Trial

Stem Cell Therapy Shows Safety, Possible Efficacy in Early Trial

298232

Stem Cell Therapy Shows Safety, Possible Efficacy in Early Trial

Treatment with ISC-hpNSC, an investigational stem cell therapy for Parkinson’s disease, was safe and well-tolerated over at least two years in an early clinical trial in 12 patients. Results from the small trial, which treated patients at low, medium and high doses, also indicate that the therapy eased Parkinson’s-related symptoms and improved quality of life. In the open-label Phase 1 trial (NCT02452723), conducted at the Royal Melbourne Hospital in Australia, adults ages 30 to 70, with moderate…

You must be logged in to read/download the full post.